Marshall Wace LLP purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 24,501 shares of the company's stock, valued at approximately $577,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. KBC Group NV boosted its stake in Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after acquiring an additional 978 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after buying an additional 721 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Dyne Therapeutics during the 4th quarter valued at about $257,000. Magnetar Financial LLC purchased a new stake in Dyne Therapeutics in the fourth quarter valued at about $263,000. Finally, E Fund Management Co. Ltd. boosted its holdings in Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after acquiring an additional 1,249 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.
Insider Buying and Selling
In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is owned by company insiders.
Dyne Therapeutics Price Performance
Shares of NASDAQ DYN opened at $11.86 on Friday. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -3.33 and a beta of 1.21. The firm's 50 day simple moving average is $10.58 and its 200-day simple moving average is $18.98. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $47.45.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. Analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on the stock. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. JPMorgan Chase & Co. decreased their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. HC Wainwright reissued a "buy" rating and set a $46.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 17th. Royal Bank of Canada restated an "outperform" rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Finally, Scotiabank began coverage on Dyne Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $47.46.
View Our Latest Research Report on DYN
Dyne Therapeutics Profile
(
Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
